SACCHARIN SODIUM ANHYDROUS
Molecular Excipient
| Mwt. | LogP | HBD | HBA | PSA | RB | CSP3 | 
|---|---|---|---|---|---|---|
| 182.0 | -0.5 | 0 | 3 | 70.0 | 0 | 0.0 | 
- CAS
- 128449
- UNII
- I4807BK602
- SYNONYMS
- 
                                
- ZINC ID(s)
- Availability
- Present in 80 ZINC catalogs
Known Active Genes
                        
                            This compound has been observed to have activity at 10μM or less against the following gene(s).
                        
                    
                    
                    | Name | Description | Classification | 
|---|---|---|
| A6YCJ1_9METZ | Astrosclerin-3 | Unclassified / Unclassified | 
| CA | Carbonic anhydrase | Unclassified / Unclassified | 
| NCE103 | Carbonic anhydrase | Enzyme / Enzyme-Other | 
| MTCA2 | Carbonic anhydrase 2 | Enzyme / Enzyme-Other | 
| CA7 | Carbonic anhydrase 7 | Enzyme / Enzyme-Other | 
| CA4 | Carbonic anhydrase 4 | Enzyme / Enzyme-Other | 
| MTCA1 | Beta-carbonic anhydrase 1 | Enzyme / Enzyme-Other | 
| CA2 | Carbonic anhydrase 2 | Enzyme / Enzyme-Other | 
| CA12 | Carbonic anhydrase 12 | Enzyme / Lyase | 
| CA6 | Carbonic anhydrase 6 | Enzyme / Lyase | 
| CA14 | Carbonic anhydrase 14 | Enzyme / Lyase | 
| CA9 | Carbonic anhydrase 9 | Enzyme / Lyase | 
| CA1 | Carbonic anhydrase 1 | Enzyme / Lyase | 
| CA5B | Carbonic anhydrase 5B, mitochondrial | Enzyme / Lyase | 
Clinical Trials
                            
                                This compound has been an intervention in the following clincial trials (per clinicaltrials.gov).
                            
                        
                        
                        | Code | Date | Title | Phase | Status | 
|---|---|---|---|---|
| NCT02318446 | 2015-03-01 | Efficacy Study of Folic Acid Supplementation in Adolescent Epileptics | Phase 3 | Not Yet Recruiting | 
(Browse) Purchasable Analogs in ZINC
Dosages
| Route | Formulation | Per Unit Dose | 
|---|---|---|
| Im - Iv | Injection | 0.09% | 
| Intramuscular | Injection | |
| Iv(Infusion) | Injection | 0.09% | 
| Oral | Emulsion | 0.04% | 
| Oral | Liquid | 0.04% | 
| Oral | Powder, For Solution | |
| Oral | Powder, For Suspension | 0.38% | 
| Oral | Solution | 0.67% | 
| Oral | Solution, Elixir | |
| Oral | Suspension | 0.33% | 
| Oral | Syrup | 0.08% | 
| Oral | Tablet | 2.08MG | 
| Oral | Tablet (Immed./comp. Release), Uncoated, Chewable | 7.5MG | 
| Oral | Tablet, Film Coated | 0.32MG | 
| Oral | Wafer | 2.75MG | 
| Rectal | Liquid | 0.04% | 
| Rectal | Solution | 0.67% |